Robuta

https://www.prnewswire.com/news-releases/neurocrine-to-acquire-soleno-therapeutics-expanding-its-endocrinology-and-rare-disease-portfolio-302734531.html Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio Apr 6, 2026 - VYKAT™ XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy... rare disease portfolio endocrinology and neurocrine acquire soleno https://www.businesswirechina.com/en/news/62859.html Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio -... rare disease portfolio chiesi group acquire pharmaceuticals expanding